Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Steve Stiles

  • News

    Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes

    January 19, 2021

    Together, four “easily measured” biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.

  • News

    Calcium burden drives CV risk whether coronary disease is obstructive or not

    December 10, 2020

    That future cardiovascular risk tracks closely with plaque burden, but not so much with whether the coronary disease is obstructive, may never have been so clearly illustrated.

  • 1
    News

    The socioeconomic revolving door of 30-day heart failure readmissions

    October 9, 2020

    Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital care quality or insurance coverage, a study suggests.

  • News

    ‘Cautious’ DOAC underdosing in AFib may push mortality higher

    September 21, 2020

    Risk-averse clinicians might be doing more harm than good by prescribing direct oral anticoagulants at lower-than-recommended dosages in hope of avoiding bleeding complications, suggests a study.

  • 1
    News

    Minidose edoxaban may safely cut AFib stroke risk in the frail, very elderly

    September 3, 2020

    Those who took the factor Xa inhibitor edoxaban (Savaysa) at the off-label dosage of 15 mg once daily showed a two-thirds drop in risk for stroke or systemic embolism, compared with patients who received placebo.

  • 1
    News

    All NSAIDs raise post-MI risk but some are safer than others: Next chapter

    August 5, 2020

    A new cohort analysis extends NSAID cautions in high-CV-risk patients to a Korean population. Some question whether the steep climbs in risk seen for some of the drugs are real.

  • 1
    News

    Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure

    July 31, 2020

    Recovery from acute COVID-19 isn’t necessarily the end of it, clearly. Two reports aim to clarify how SARS-CoV-2 can directly invade the heart and indirectly cause persisting myocardial injury.

  • 1
    News

    Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF

    June 26, 2020

    The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.

  • News

    Signature STEMI sign may be less diagnostic in the COVID-19 age

    April 22, 2020

    ST-segment elevation, often a ticket to the cath lab, may not indicate STEMI as reliably as before hospitals started to fill with COVID-19 patients, who may have other ST-segment–elevating conditions.

  • 1
    News

    DAPA-HF: Dapagliflozin benefits regardless of age, HF severity

    November 25, 2019

    PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.

Previous1 2
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences